NEXIMMUNE, INC.
9119 Gaither Road
Gaithersburg, MD 20877
March 14, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Ansart
| RE: | NexImmmune, Inc. |
Registration Statement on Form S-3
Filed March 9, 2022
File No. 333-263399
Acceleration Request
Dear Ms. Ansart:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of NexImmune, Inc. (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to Wednesday, March 16, 2022, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call John Rudy of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
| Very truly yours, |
| NEXIMMUNE, Inc. |
| /s/ John Trainer |
| John Trainer |
| Chief Financial Officer |
| cc: | John Rudy, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |